Coexpression of p53 and c-erbB-2 proteins is associated with histological type, tumour stage, and cell proliferation in malignant salivary gland tumours

Virchows Archiv

Volumn 428, Issue 2, 1996, Pages 75-83

  Kamio, Naohiko ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma; c erbB 2; Ki 67; Salivary gland; Tumour

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CELL PROLIFERATION; FEMALE; GENE AMPLIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; ONCOGENE C ERB; PLEOMORPHIC ADENOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT; TISSUE NECROSIS;

EID: 0029888090     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00193934     Document Type: Article

References (29)

1. Azuma M, Kasai Y, Tamatani T, Sato M (1992) Involvement of p53 mutation in the development of human salivary gland pleomorphic adenomas. Cancer Lett 65:61-71
2. Baas IO, Mulder JR, Offerhaus GJA, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasmas. J Pathol (Lond) 172:5-12
3. Barbareschi M, Leonardi E, Mauri FA, et al (1992) p53 and c-erbB-2 protein expression in breast carcinomas: an immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer. Am J Clin Pathol 98:408-418
4. Barnes DM, Dublin EA, Fisher CJ, et al (1993) Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis. Hum Pathol 24:469-476
5. Brambilla E, Gazzeri S, Mor D, et al (1993) Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 143:199-210
6. Cattoretti G, Rilke F, Andoreola S, et al (1988) p53 expression in breast cancer. Int J Cancer 41:178-183
7. Deguchi H, Hamano H, Hayashi Y (1993) c-myc, ras p21, and p53 expression in pleomorphic adenoma and its malignant form of the human salivary glands. Acta Pathol Jpn 43:413-422
8. Delahunt B, Bethwaite PB, Thornton A, Ribas JL (1995) Proliferation of renal cell carcinoma assessed by fixation-resistant polyclonal Ki-67 antibody labeling. Cancer 75:2714-2719
9. Ellis GL, Auclair PL (1991) Classification of salivary gland neoplasms. In: Ellis GL, Auclair PL, Gnepp DR (eds) Surgical pathology of the salivary glands. Saunders, Philadelphia, pp 318-332
10. Fearon ER, Volgelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759-767
11. Haerslev T, Jacobsen GK (1995) An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen, and prognosis. Hum Pathol 26:295-301
12. Hurlimann J, Saraga EP (1994) Expression of p53 protein in gastric carcinomas. Am J Surg Pathol 18:1247-1253
13. Ishii K, Nakajima T (1994) Evaluation of malignant grade of salivary gland tumors: studies by cytofluorometric nuclear DNA analysis, histochemistry for nucleolar organizer regions and immunohistochemistry for p53. Pathol Int 44:287-296
14. Isola J, Visakorpi T, Holli K, Kallioniemi O-P (1992) Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-positive breast cancer patients. J Natl Cancer Inst 84:1109-1114
15. Kernohan NM, Blessing K, King G, Corbett IP, Miller ID (1991) Expression of c-erbB-2 oncoprotein in salivary gland tumors: an immunohistochemical study. J Pathol (Lond) 163:81-85
16. Martin HM, Filipe MI, Morris RW, et al (1992) p53 Expression and prognosis in gastric carcinoma. Int J Cancer 50:859-862
17. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barenes DM (1992) Analysis of p53 expression in human tumors: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 101:183-189
18. Murakami M, Ohtani I, Hojo H, Wakasa H (1992) Immunohistochemical evaluation with Ki-67: an application to salivary gland tumours. J Laryngol Otol 106:35-38
19. Nagao T, Kondo F, Sato T, Nagato Y, Kondo Y (1995) Immunohistochemical detection of aberrant p53 expression in hepatocelluar carcinoma. Hum Pathol 26:326-333
20. Press MF, Pike MC, Hung G, Zhou JY, Ma Y, George J, Dietz-Band J, James W, Slamon JG, Batsakis JG, El-Naggar AK (1994) Amplication and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675-5682
21. Sasano H, Miyazaki S, Gooukon Y, et al (1992) Expression of p53 in human esophageal carcinoma: an immunohistochemical study with correlation to proliferating cell nuclear antigen expression. Hum Pathol 23:1238-1243
22. Seifert G (1991) Histological typing of salivary gland tumours. (World Health Organization) Springer, Berlin Heidelberg New York
23. Shrestha P, Huang JW, Tsuji T, Shinozaki F, Maeda K, Sasaki K, Ueno K, Yamada K, Mori M (1992) Rare expression of the c-erbB-2 oncoprotein in salivary gland tumors: immunohistochemical study. J Oral Pathol Med 21:477-480
24. Slamon DJ, Godolphin W, Jones LA, et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
25. Spiro RH, Huvos AG, Strong EW (1982) Adenocarcinoma of salivary gland origin: clinicopathologic study of 204 patients. Am J Surg 144:423-431
26. Sugano S, Mukai K, Tsuda H, Hirohashi S, Furuya S, Shimosato Y, Ebihara S, Takeyama I (1992) Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102:923-927
27. Thackray AC, Lucas RB (1974) Tumors of the major salivary glands. Armed Forces Institute of Pathology, Washington, DC
28. Van den Berg FM, Tigges AJ, Schipper MEI, et al (1989) Expression of the nuclear oncogene p53 in colon tumours. J Pathol (Lond) 157:193-199
29. Wiltschke C, Kindas-Mueggen I, Steininger A, Reiner A, Reiner G, Preis PN (1994) Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol 120:737-742